Vascular risk factors may be associated with amyloid-beta (Aβ) burden in individuals who do not take vascular medications; however, this association is not evident in individuals who take vascular medications. This may possibly be due to moderation of Aβ deposition by vascular medications.
Why this matters
Vascular risk factors are thought to increase Alzheimer’s disease (AD) risk by promoting cardiovascular disease and Aβ accumulation. Recent evidence suggests that vascular medications may moderate this link by providing protection against Aβ deposition. Understanding the link between vascular risk factors and AD pathogenesis, as well as the effect of vascular medications on this is necessary for treatment development for AD.